News

Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.
Zacks Investment Research on MSN2dOpinion
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical - Products industry is expected to face growing uncertainty as the United States reimposes tariffs. Tariffs ...
The Global Weight Management Market is expected to witness a growth rate of 9-10% by 2029. The market has experienced ...
Detailed price information for Sensus Healthcare Inc (SRTS-Q) from The Globe and Mail including charting and trades.
Q1 2025 Earnings Call Transcript May 14, 2025 Allurion Technologies Inc. beats earnings expectations. Reported EPS is $0.43, expectations were $-1.53. Operator: Hello, everyone, and welcome to ...
Discover Allurion Technologies' Q1 2025 earnings highlights, featuring a revamped B2B2C strategy, FDA progress, improved margins, and future growth plans.
Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ETCompany ParticipantsTara Brady - Interim CFOShantanu Gaur ...
Allurion Technologies, Inc. (ALUR) delivered earnings and revenue surprises of 128.10% and 2.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the ...
Allurion Technologies, Inc. (NYSE: ALUR) ("Allurion" or the "Company"), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a ...
Everus Construction Group reported quarterly earnings of 72 cents per share which beat the analyst consensus estimate of 43 cents per share. The company reported quarterly sales of $826.63 million ...
GLP-1s used in combination with the Virtual Care Suite led to an average gain in lean body mass of 6.1%, the company said. Data was also presented showing that Allurion Balloon used in combination ...
Detailed price information for Stereotaxis Inc (STXS-A) from The Globe and Mail including charting and trades.